Point72 Middle East FZE’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-25,800
Closed -$4M 10
2023
Q4
$4M Sell
25,800
-61,200
-70% -$8.92M 0.12% 238
2023
Q3
$13M Buy
87,000
+29,800
+52% +$4.37M 0.42% 43
2023
Q2
$7.71M Buy
57,200
+49,900
+684% +$7.32M 0.21% 111
2023
Q1
$1.16M Sell
7,300
-5,800
-44% -$887K 0.04% 464
2022
Q4
$2.12M Buy
+13,100
New +$2.01M 0.09% 293

Other funds holding ABBV

Point72 Middle East FZE's ABBV Position: Q1 2024 in Review

Point72 Middle East FZE sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 125,199 shares — an estimated $19.4M sold.

Point72 Middle East FZE first reported a position in ABBV in Q2 2023 and held it in 3 quarters. The position peaked at $27.6M in Q3 2023. 3,380 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

  • Point72 Middle East FZE reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 125,199 AbbVie shares in Q1 2024, an estimated $19.4M.
  • Point72 Middle East FZE first reported a position in AbbVie in Q2 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's AbbVie position peaked at $27.6M in Q3 2023.
  • 3,380 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.